I am honored to be joining Volpara Solutions to help this highly accomplished team drive adoption of its industry leading breast imaging density and quantitative breast imaging tools that are rapidly becoming the industry gold standard,” said Pavlidis.
WELLINGTON, New Zealand (PRWEB) March 03, 2015
Volpara Solutions, leaders in the development of quantitative breast imaging tools, announced that John D. Pavlidis has joined their Board of Directors. Pavlidis brings more than 25 years of technical and executive management experience in the medical industry, including more than 15 years as CEO of large and small organizations.
“John’s broad management experience in breast imaging and across a variety of medical imaging modalities will be a tremendous asset to the sales, product marketing and development teams as they continue to focus on the global adoption of Volpara Solutions’ suite of quantitative breast imaging tools. We are pleased to add John’s extensive expertise and proven track record for implementing on a clear strategic vision in a supportive, cohesive environment,” said Chief Executive Officer Ralph Highnam, Ph.D., and one of the founders of Volpara Solutions.
Pavlidis currently serves on the Boards of Directors for Clario Medical and DySIS Medical and served on the Board for U-Systems, the pioneer and leader in automated breast ultrasound screening, which was acquired by GE Healthcare in 2012. Most recently, Pavlidis was president and CEO of Estech, a leader in minimally invasive surgical cardiac ablation devices, until the company was acquired by AtriCure in 2013. Previously, he served as president and CEO of R2 Technology, the pioneer and leader in Computer Aided Detection of breast and lung abnormalities, where he directed the company through a successful acquisition by Hologic. Before joining R2 Technology, Pavlidis served as president of the worldwide Ultrasound Division of Siemens Healthcare after holding positions of steadily increasing responsibility within Siemens in both the U.S. and Germany beginning in 1990. This included business and technical responsibilities in Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Ultrasound.
Pavlidis earned a bachelor’s degree in Biomedical Engineering from Rensselaer Polytechnic Institute, Troy, NY, as well as a master’s degree in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College, Hanover, NH.
“Throughout my career, my goal has always been to improve health and well-being by helping high quality medical device companies succeed. I am honored to be joining Volpara Solutions to help this highly accomplished team drive adoption of its industry leading breast imaging density and quantitative breast imaging tools that are rapidly becoming the industry gold standard,” said Pavlidis.
Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images to help doctors evaluate who might benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the ACR (American College of Radiology) breast density categories. To date, more than 4-million women have had their breast density analyzed, using VolparaDensity. VolparaDensity is part of a suite of quantitative breast imaging tools built on the VolparaSolutions algorithm that allows for personalized measurements of density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in breast screening.
About Volpara Solutions
Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Cleared by the FDA, HealthCanada, the TGA, and CE-marked, VolparaDensity provides an objectively volumetric measure of breast density from both digital mammography and tomosynthesis images. VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in breast screening. For more information, visit http://www.volparasolutions.com
# # #
Chris K. Joseph